| Indicators | Browse All

Gyre Therapeutics, Inc. (GYRE)

Healthcare | Biotechnology | San Diego, United States | NasdaqCM
6.87 USD -0.18 (-2.486%) ⇩ (Oct. 12, 2026, 4 p.m. EDT)
Short-term:★☆☆☆☆Long-term:★☆☆☆☆Dividends:☆☆☆☆☆
Hot Take ↕ | Oct. 10, 2026, 4:39 a.m. EDT

Gyre Therapeutics presents a classic value trap with deteriorating fundamentals and no safety net. The business is actively shrinking, with revenue falling 2.1% year-over-year and operating margins collapsing to -47.6%. While the balance sheet currently shows a healthy current ratio of 4.26, the company is burning cash with negative operating cash flow of nearly $5 million, and the massive short interest (nearly 25% of float) signals deep skepticism among sophisticated players. The stock has lost over 96% of its value over the last nine years, a structural decline that ignores any temporary recovery in recent quarters. There is no dividend to provide income, and the options market is completely silent, offering no hedge or speculative cover. With a forward P/E of 117 based on tiny estimated earnings and a history of widening losses, the risk-reward profile is severely skewed against the buyer.
Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoARIMA ✓0.158652
AutoTheta0.160811
AutoETS0.161202
MSTL0.163802

Forecast horizon: 45 days | Selected: AutoARIMA

Forecast Reliability
Score 40%
H-stat 2.66
Ljung-Box p 0.000
Jarque-Bera p 0.758
Excess Kurtosis -0.07
Attribute Value
Sector Healthcare
Last Dividend Date 2023-01-12
Debt to Equity Ratio 2.073
Revenue per Share 1.172
Market Cap 727,921,728
Forward P/E 114.42
Beta 4.74
Profit Margins -19.33%
Website https://www.gyretx.com

As of Oct. 10, 2026, 4:39 a.m. EDT: Options activity is sparse and lacks directional conviction. Implied volatility is extremely low across all expirations, indicating a lack of speculative interest. Open interest is negligible, with only a single contract noted at the $10 strike for calls and a few contracts at-the-money or slightly out-of-the-money for both sides. This silence suggests the market views the stock as illiquid and devoid of immediate catalysts driving significant price movement.

Dividend Data

Dividend History
Date Dividend Yield %
2023-01-13 3.600 92.307690
2022-09-21 21.450 286.000000
2015-08-20 896.175 59.270833
Additional Data
dividendYield 0.0
trailingAnnualDividendRate 0.0
trailingAnnualDividendYield 0.0
lastDividendValue 3.6
lastDividendDate 2023-01-13
dividendDate 2023-01-12

Info Dump

Attribute Value
52 Week Change -0.14232212
Address1 12,730 High Bluff Drive
Address2 Suite 250
All Time High 47,990.25
All Time Low 2.85
Ask 8.94
Ask Size 2
Audit Risk 8
Average Daily Volume10 Day 123,470
Average Daily Volume3 Month 106,334
Average Volume 106,334
Average Volume10Days 123,470
Beta 4.738
Bid 5.04
Bid Size 2
Board Risk 9
Book Value 1.018
City San Diego
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 7
Country United States
Crypto Tradeable 0
Currency USD
Current Price 6.865
Current Ratio 4.259
Custom Price Alert Confidence HIGH
Date Short Interest 1,790,726,400
Day High 7.065
Day Low 6.85
Debt To Equity 2.073
Display Name Gyre Therapeutics
Dividend Date 1,673,481,600
Dividend Yield 0.0
Earnings Timestamp 1,786,105,800
Earnings Timestamp End 1,793,881,800
Earnings Timestamp Start 1,793,881,800
Ebitda -12,131,000
Ebitda Margins -0.11046
Enterprise To Ebitda -58.819
Enterprise To Revenue 6.497
Enterprise Value 713,534,784
Eps Forward 0.06
Eps Trailing Twelve Months -0.25
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 15
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 6.864
Fifty Day Average Change 0.0009999275
Fifty Day Average Change Percent 0.00014567708
Fifty Two Week Change Percent -14.232212
Fifty Two Week High 9.42
Fifty Two Week High Change -2.5550003
Fifty Two Week High Change Percent -0.27123144
Fifty Two Week Low 5.44
Fifty Two Week Low Change 1.4249997
Fifty Two Week Low Change Percent 0.26194847
Fifty Two Week Range 5.44 - 9.42
Financial Currency USD
First Trade Date Milliseconds 1,144,848,600,000
Float Shares 35,941,204
Forward Eps 0.06
Forward P E 114.416664
Free Cashflow 1,875,250
Full Exchange Name NasdaqCM
Full Time Employees 625
Fullday Change 0.14500046
Fullday Change Percent 2.11217
Fullday Price 7.01
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,790,812,800
Gross Margins 0.93802
Gross Profits 103,011,000
Has Pre Post Market Data 1
Held Percent Insiders 0.74396
Held Percent Institutions 0.082399994
Implied Shares Outstanding 106,033,763
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Dividend Date 1,673,568,000
Last Dividend Value 3.6
Last Fiscal Year End 1,767,139,200
Last Split Date 1,698,710,400
Last Split Factor 1:15
Long Business Summary Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Long Name Gyre Therapeutics, Inc.
Market us_market
Market Cap 727,921,728
Market State PRE
Max Age 86,400
Message Board Id finmb_100542295
Most Recent Quarter 1,782,777,600
Net Income To Common -19,908,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 786,240,352
Number Of Analyst Opinions 3
Open 7.0
Operating Cashflow -4,935,000
Operating Margins -0.47624
Overall Risk 8
Payout Ratio 0.0
Phone 858-284-0115
Pre Market Change 0.14500046
Pre Market Change Percent 2.11217
Pre Market Price 7.01
Pre Market Time 1,791,880,803
Previous Close 7.04
Price Hint 2
Price To Book 6.7436147
Price To Sales Trailing12 Months 6.6284375
Profit Margins -0.19326
Quick Ratio 3.587
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.175
Regular Market Change Percent -2.4858
Regular Market Day High 7.065
Regular Market Day Low 6.85
Regular Market Day Range 6.85 - 7.065
Regular Market Open 7.0
Regular Market Previous Close 7.04
Regular Market Price 6.865
Regular Market Time 1,791,835,201
Regular Market Volume 81,952
Return On Assets -0.05421
Return On Equity -0.17442
Revenue Growth -0.021
Revenue Per Share 1.172
Sand P52 Week Change 0.17318833
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 7
Shares Outstanding 106,033,763
Shares Percent Shares Out 0.018099999
Shares Short 1,918,512
Shares Short Previous Month Date 1,788,134,400
Shares Short Prior Month 1,709,352
Short Name Gyre Therapeutics, Inc.
Short Percent Of Float 0.0645
Short Ratio 10.4
Source Interval 15
State CA
Symbol GYRE
Target High Price 20.0
Target Low Price 18.0
Target Mean Price 18.66667
Target Median Price 18.0
Total Cash 74,796,000
Total Cash Per Share 0.705
Total Debt 3,418,000
Total Revenue 109,818,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.25
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 7.0713
Two Hundred Day Average Change -0.20630026
Two Hundred Day Average Change Percent -0.029174304
Type Disp Equity
Volume 81,952
Website https://www.gyretx.com
Zip 92,130